ArriVent BioPharma (AVBP) has drawn attention after recent trading, with the share price closing at US$24.89. Investors are weighing this clinical stage cancer drug developer’s profile against its current valuation signals.

That closing share price of US$24.89 comes after a 2.77% 1 day share price return and a 16.15% 7 day share price return. The 30 day share price return of 1.43% contrasts with a 19.66% 90 day share price return and a 51.58% 1 year total shareholder return, pointing to momentum that has picked up again after a recent pause.

If you are looking for similar oncology and biotech ideas using AI, it is worth scanning a wider field with the 36 healthcare AI stocks

With no revenue yet, a loss of US$166.308 million, and a market cap of about US$1.1b, the share price already bakes in meaningful expectations. This raises the question of whether ArriVent is undervalued today or if the market is already pricing in future growth.

Discounted Cash Flow points to a wide gap between price and model value

The SWS DCF model estimates a fair value of $180.06 for ArriVent BioPharma, compared with the recent $24.89 close, implying a large valuation gap.

The DCF approach projects a company’s potential future cash flows and then discounts them back to today’s dollars using a required rate of return. In ArriVent’s case, this means extending assumptions around when a currently loss making, pre revenue biotech could start generating cash and what those future cash flows might look like.

For a clinical stage biotech with no revenue and a net loss of $166.308 million, this kind of model is heavily influenced by expectations around clinical outcomes, regulatory approvals, partnering structures and eventual pricing. Even small shifts in those inputs can move the estimated fair value by a wide margin. This helps explain why the DCF output can differ so much from the market price at this stage of the company’s life cycle.

Result: DCF Fair value of $180.06 (UNDERVALUED)

However, you also need to factor in the clinical trial uncertainty and the current US$166.308 million loss, which could shift sentiment quickly.

Another view from market pricing

While the SWS DCF model points to a large gap to fair value, the current P/B ratio tells a different story. At 3.6x, ArriVent trades below a peer average of 34.1x, yet above the broader US biotechs average of 2.3x. How should you interpret that mixed signal?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out ArriVent BioPharma for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 59 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With such a mix of strong recent returns and clear clinical and valuation questions, this is a moment to look closely and act on your own judgment. Take a few minutes to review both sides of the story by checking the 1 key reward and 3 important warning signs

Ready to uncover more investment ideas?

If ArriVent has caught your attention, do not stop here. Broaden your watchlist with focused stock ideas that match different risk and return preferences.

• Target potential value opportunities by scanning companies that look overlooked on quality and price using the 59 high quality undervalued stocks.
• Anchor your portfolio with companies that pair income potential and resilience through the 13 dividend fortresses.
• Spot less crowded opportunities with strong fundamentals before the crowd catches on by checking the screener containing 25 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.